Core Insights - Iridex Corporation announced a new study published in Translational Vision Science & Technology, focusing on the thermal dynamics of transscleral laser treatments for glaucoma [1][5] Group 1: Study Overview - The study, led by Dr. Tomas M. Grippo, provides the first quantitative computer model comparing the thermal effects of continuous wave transscleral cyclophotocoagulation (CW-TSCPC) and MicroPulse laser therapy [2] - Advanced Monte Carlo simulations were used to model the heating effects on the ciliary body, revealing that CW-TSCPC produced a 2 mm-wide zone of tissue heating exceeding 100°C for approximately 2.2 seconds, while MicroPulse TLT generated a smaller thermal zone of 0.6-1.2 mm with peak temperatures below 100°C [3] Group 2: Implications and Future Directions - The study suggests that both techniques share a thermal continuum and may evolve to serve distinct roles in treating glaucoma, from refractory cases to earlier interventions [4] - The findings enhance the understanding of how these laser treatments interact with ocular tissues, potentially leading to improved treatment optimization and safety in glaucoma management [5] Group 3: Company Background - Iridex Corporation is a leader in developing laser-based medical systems for ophthalmology, with products used for treating glaucoma and diabetic macular edema [6] - The company's proprietary MicroPulse technology minimizes tissue damage while delivering effective laser treatment, and its products are marketed in over 100 countries [6]

Core Viewpoint - Iridex Corporation, a leader in laser-based medical systems for ophthalmology, will participate in the Sidoti Year-End Virtual Investor Conference on December 11, 2025 [1][2]. Company Overview - Iridex Corporation specializes in developing, manufacturing, and marketing innovative laser-based medical systems, including capital equipment and consumable probes for the ophthalmology market [3]. - The company's proprietary MicroPulse technology provides effective laser treatment while minimizing tissue damage, making it a safe option for treating sight-threatening eye conditions [3]. - Iridex's product line is utilized for treating glaucoma, diabetic macular edema (DME), and other retinal diseases, with sales occurring in the U.S. through a direct sales force and internationally via independent distributors in over 100 countries [3].